Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stake Decreased by Vivo Capital LLC

Vivo Capital LLC decreased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 21.1% during the fourth quarter, Holdings Channel reports. The fund owned 1,784,006 shares of the company’s stock after selling 478,194 shares during the period. Tarsus Pharmaceuticals makes up about 3.0% of Vivo Capital LLC’s holdings, making the stock its 10th biggest holding. Vivo Capital LLC owned 0.05% of Tarsus Pharmaceuticals worth $36,126,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in Tarsus Pharmaceuticals by 362.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock valued at $78,000 after acquiring an additional 3,004 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Tarsus Pharmaceuticals by 65.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after purchasing an additional 2,092 shares during the period. Raymond James & Associates bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth $180,000. Ieq Capital LLC bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth $193,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth $198,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS traded down $2.56 during mid-day trading on Thursday, hitting $34.79. The stock had a trading volume of 476,664 shares, compared to its average volume of 707,329. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.93. The company has a 50 day moving average of $34.32 and a two-hundred day moving average of $26.09. Tarsus Pharmaceuticals, Inc. has a twelve month low of $12.57 and a twelve month high of $42.50. The firm has a market cap of $1.31 billion, a PE ratio of -7.50 and a beta of 1.10.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same period in the previous year, the company earned ($0.49) earnings per share. Research analysts predict that Tarsus Pharmaceuticals, Inc. will post -4.25 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $149,297.40. Following the sale, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at $1,981,870.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, COO Seshadri Neervannan sold 4,879 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the sale, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 4,436 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $135,741.60. Following the sale, the general counsel now directly owns 40,951 shares in the company, valued at $1,253,100.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,496 shares of company stock valued at $749,578. 11.54% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright increased their price target on Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Barclays raised their price objective on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. Jefferies Financial Group raised their price objective on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, February 29th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price target (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.38.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.